TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01284049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%®
Description: Administration of Intralipid 20%® at a dose ranging between 0.5 and 1 g/kg/infusion during 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMEGAVEN 10%®
Description: OMEGAVEN 10%® will be used as the sole lipid supplement at a dose of 0.5 to 1.0 g/kg/Infusion with a maximum dose per infusion of 40 grams, in view of formulation constraints during 12 weeks.
Study: NCT02054481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066
Description: Medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066
Description: High dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066
Description: Low dose
Study: NCT00912665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Doppler Flowmetry
Description: blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: squatting
Description: Subjects will perform squatting for 6 minutes while either blood flow or intraocular pressure measurements

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suction cup
Description: Experimental stepwise increase of intraocular pressure while either optic nerve head blood flow or intraocular pressure measurements
Study: NCT05173545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Description: Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first).~5% Glucose Injection drugs dissolved in 250 ml, intravenous drip for 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Description: Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first).~5% Glucose Injection drugs dissolved in 250 ml, intravenous drip for 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Description: Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first).~5% Glucose Injection drugs dissolved in 250 ml, intravenous drip for 60 minutes.
Study: NCT00852332

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere
Study: NCT03660670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ONCORAL therapeutic education
Description: Multidisciplinary program that includes informative cessions with a hospital pharmacist about the anticancer drug: information is given to the patients on adverse events and their managements, optimizing drug dosage plans. Moreover, information is shared with town partners: doctor, pharmacists, and nurses.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Standard of care
Description: In the group of standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessments.
Study: NCT00982566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
Study: NCT02498210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In Vitro Maturation Procedure
Description: POR patients will be treated in IVM cycle. After baseline evaluation on day 3, 150 IU/day recombinant FSH or HMG will be added for 3 days. A second evaluation will be performed on day 6 of the menstrual cycle. An injection of 10,000 IU hCG (Pregnyl; Organon, Oss, Holland) or Ovitrelle 250mcg (Merck Serono ) will be administered subcutaneously when the endometrial thickness will be ≥6 mm and the leading follicle will be at least 12 mm. Oocyte retrieval will be performed under ultrasound guidance with a 19G single-lumen aspiration needle (Cook; Queensland, Australia). The follicular fluid will be collected in culture tubes containing follicle flush buffer (Cook) with 2 IU/ml heparin. All aspirates were filtered to identify additional oocytes
Study: NCT01972321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology supported supervision
Description: CHWs will be provided with mobile phones and solar chargers to carry out the following:~1. Establish closed user groups (CUGs) to enable two-way communication between CHWs and their supervisors free of charge to the users.~2. Data submission through mobile phones 2.1. receive motivational performance related feedback provided in response. 2.2. Automated messages to supervisors which 2.2.1. Flags problems and strengths/successes identified in CHWs data 2.2.2. Alerting supervisors as to which CHWs require targeted supervision. 2.3. CHWs data summarised in a user friendly format and made accessible to district statisticians~3. Monthly motivational short message service (SMS) messages provided to CHWs that are locally relevant to CHW work and that are designed to impact positively on CHW performance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community supported supervision
Description: CHWs will facilitate the clubs using a learning, planning and action cycle. Club members will rank child health challenges faced by their community using picture cards and decide which one to focus on for each cycle. They will discuss solutions, which include supporting CHWs services, and take actions to meet challenges. They will also promote group decision-making and ownership and through this process gain tangible results. Solutions to health challenges developed by club members are a key focus of the village health club approach. Village Health Clubs are based on 5 guiding principles: clubs are open to all, village owned, intended to support CHW work, strength based, and fun and focused.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated community case management
Description: Implementation of integrated community case management, with provision of training and equipment to CHWs for diagnosis and treatment of malaria, pneumonia and diarrhoea in children less than 5 years of age. Supportive supervision of CHWs will be provided by assigned health facility supervisors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated community case management
Description: Implementation of integrated community case management, with provision of training and equipment to CHWs for diagnosis and treatment of malaria, pneumonia and diarrhoea in children less than 5 years of age. Supportive supervision of CHWs will be provided by assigned health facility supervisors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated community case management
Description: Implementation of integrated community case management, with provision of training and equipment to CHWs for diagnosis and treatment of malaria, pneumonia and diarrhoea in children less than 5 years of age. Supportive supervision of CHWs will be provided by assigned health facility supervisors.
Study: NCT02543242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InToneTM (InControl Medical, LLC) - Medical Device
Study: NCT02456220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Herbst appliance
Description: Group treated with conventional Herbst appliance for mandibular advancement during orthopedic treatment.
Study: NCT01128387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: dose escalating 1.5mg/kg or 2.5mg/kg weekly during radiation. Cisplatin on Days 1 and 29, Fluorouracil on Days1-4 and Days 29-32.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: dose escalating 1.5mg/kg or 2.5mg/kg weekly during radiation. Cisplatin on Days 1 and 29, Fluorouracil on Days1-4 and Days 29-32.
Study: NCT03591887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABY-035
Description: ABY-035 solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABY-035
Description: ABY-035 solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABY-035
Description: ABY-035 solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABY-035
Description: ABY-035 solution for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to ABY-035 solution for injection
Study: NCT02204865

Intervention type: DEVICE
Intervention: Pacemaker/ICD
Description: Implantation of an ICD or CRT device with ApneaScan function
Study: NCT00389207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nevirapine bid
Description: nevirapine twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nevirapine qd
Description: nevirapine once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atazanavir
Description: atazanavir once daily
Study: NCT03182530

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ulnar artery compression device
Description: a radial compression device will be applied at the access site. another closure device will be used for ipsilateral ulnar artery compression for 1-hour duration in order to increase peak velocity blood flow into the radi¬al artery. neither pulse oxymetry nor duplex ultrasonography will be performed in case of ulnar artery compression. after ulnar artery compression, the initial compression of the radial artery will be reduced by letting up the pressure until bleeding will be seen and then adding minimal pressure whenever needed in order to maintain radial artery patency.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radial artery compression device guided with plysthmography
Description: a radial compression device will be applied at the access site. A pulse oximeter sensor was placed over the index finger. Transient ipsilateral ulnar artery will be occluded manually to evaluate the status of radial artery patency by plethysmography (digital pulse analysis), and if there's lack of signal, the process of deflation and reinflation of the radial artery device's bladder will be repeated over the next 15 min to attempt re-establishment of antegrade radial artery flow without affecting hemostasis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radial artery compression device
Description: patients undergo the conventional hemostasis compression by using a radial compression device applied at the access site.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radial artery compression device
Description: patients undergo the conventional hemostasis compression by using a radial compression device applied at the access site.
Study: NCT02059824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aesthesiometer
Description: The eyelid sensation will be tested on every third by applying the tip of the aesthesiometer filament perpendicular to the eyelid skin and tarsal plate until the filament bent slightly. The filament length will be set at 6 cm (longest length) and applied to the test site 3 times. This process will be repeated 3 times and if the patient verbally responded to the 3rd touch, the number 6 will be recorder.~If the patient responded less than 3 of the 3 times, the filament will be shortened by 0.5 cm and the test will be repeated. This process will be continued by shortening the filament 0.5 cm each time, until the patient feels the filament touch 3 of 3 times. This filament length number will be recorded as the touch reading for that time period.
Study: NCT03634982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-4630
Description: RMC-4630 for oral administration
Study: NCT01598974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Acupuncture
Study: NCT00143507

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02358629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaCross™ microcatheter
Description: successful delivery, crossing, and retrieval of the investigational device as identified by confirmation of guidewire placement in the distal true lumen confirmed by angiography
Study: NCT02515253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bra prescription

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Study: NCT01598974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture
Study: NCT01903343

Intervention type: DEVICE
Intervention: shear wave elastography
Description: ultrasound
Study: NCT04627727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low FODMAP diet
Description: low FODMAP diet
Study: NCT01121718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG Intervention
Description: NIR-guided sentinel lymph node mapping with indocyanine green (ICG)
Study: NCT02912156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaway FC Tablets 200mg (Voriconazole)
Study: NCT03963973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDN-929 oral capsule
Description: low, medium and high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: matching placebo dose
Study: NCT02912156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VFEND FC Tablets 200mg (Voriconazole)
Study: NCT05480033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Technique
Description: The stages of the imagery technique included preparation of a suitable environment, preparation of the students, setting the background music (ney sound), relaxation, focusing on the technique, visualising the situation to be imagined, loading positive and constructive expressions on the individual, distracting the student from the imagined situation, relaxation and ending the session.
Study: NCT01870544

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus Rhamnosus GG
Description: LGG will be administered orally for 44 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo will be administered daily for 44 days
Study: NCT02515253

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Study: NCT03991143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH3G10
Description: intravenous
Study: NCT03550859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Rosuvastatin 40/10mg
Description: Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 40mg
Description: Telmisartan 40mg qd for 48 weeks
Study: NCT02666157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran etexilate
Description: this drug is administered twice per day for the entire study period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: this drug is administered once per day for the entire study period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: this drug is administered twice per day for the entire study period
Study: NCT00821444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone
Description: 40 mg capsule, single dose x 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B16 Fasted
Description: 40 mg tablet, single dose X 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B16 Fed
Description: 40 mg tablet, single dose X 3
Study: NCT01444092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entocort
Description: Entocort capsules, oral
Study: NCT01467635

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endobronchial ultrasound guided lymph node sampling
Description: Patients with enlarged mediastinal or hilar lymph nodes have these sampled under endobronchial ultrasound guidance using either the EBUS-TBNA needle or the EBUS-TBNB biopsy forceps.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound guided lymph node sampling
Description: Patients with enlarged mediastinal or hilar lymph nodes have these sampled under endobronchial ultrasound guidance using either the EBUS-TBNA needle or the EBUS-TBNB biopsy forceps.
Study: NCT00657410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study: NCT03991143

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous
Study: NCT01954615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg ACT-281959 prodrug formulation I (Group A)
Study: NCT00657410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT04333043

Intervention type: DIAGNOSTIC_TEST
Intervention: audiological test, cognitive questionnaires
Description: administration of cognitive and quality of life questionnaires and audiological test
Study: NCT00539760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1827771
Description: GSK1827771 will be administered using injection via subcutaneous (SC) route.
Study: NCT01497171

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elevate Mesh
Description: Transvaginal mesh repair of anterior vaginal prolapse

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Colporrhaphy
Description: Traditional suture repair of anterior vaginal prolapse
Study: NCT02712775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline (yes/no)
Study: NCT00539760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1827771
Description: GSK1827771 will be administered using injection via subcutaneous (SC) route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1827771
Description: GSK1827771 will be administered using injection via subcutaneous (SC) route.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to GSK1827771 for Injection will be administered via SC route

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to GSK1827771 for Injection will be administered via SC route
Study: NCT01954615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg ACT-281959 prodrug formulation I (Group B)
Study: NCT00539760

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to GSK1827771 for Injection will be administered via SC route
Study: NCT03234881

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOVE!
Description: Participants randomized to the MOVE!(or TeleMOVE!) arm only. MOVE! is 16 weeks of 60-minute weekly groups that are led by a physical therapist, dietician, and/or clinical health psychologist. Clinicians utilize materials available online and encourage the use, but do not require or provide food diaries. TeleMOVE! is a 90-day program utilizing technology to provide home-based messaging focusing on health education and as needed clinician contact. \*TeleMOVE! was added as an option since many in-person MOVE! programs were on pause due to the pandemic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE!+CBT
Description: Participants randomized to the MOVE!+CBT arm will attend the 16 weeks of 60-minute weekly MOVE! or 90-days of the TeleMOVE! Treatment groups, along with up to 10 clinician-led individual sessions over a 3-month period. Participants will also be given a patient treatment manual to read at home, food diaries that will be expected to be completed on a daily basis, and gradually increase daily physical activity.
Study: NCT03874312

Intervention type: DIAGNOSTIC_TEST
Intervention: Linear ultrasound (US) assessment of the internal jugular vein
Description: Evaluation of jugular vein distensibility at rest and after Valsalva maneuver by US at the time of the RHC. US-guided IJV is routinely performed at the time of vein cannulation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Linear ultrasound (US) assessment of the internal jugular vein
Description: Evaluation of jugular vein distensibility at rest and after Valsalva maneuver by US at the time of the RHC. US-guided IJV is routinely performed at the time of vein cannulation.
Study: NCT03046277

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01954615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-281959 prodrug formulation I (Groups C to G doses to be defined)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-281959 prodrug formulation I (Groups C to G doses to be defined)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-281959 prodrug formulation I (Groups C to G doses to be defined)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-281959 prodrug formulation I (Groups C to G doses to be defined)
Study: NCT01035450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Description: Everolimus-eluting stent
Study: NCT00976079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Continuous TENS use
Study: NCT01954615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-281959 prodrug formulation I (Groups C to G doses to be defined)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-281959 prodrug formulation II (Group G dose to be defined)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-246475 (Group G dose to be defined)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Groups A to F)
Study: NCT00976079

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TENS
Description: Placebo TENS use
Study: NCT01035450

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent
Description: Sirolimus-eluting stent
Study: NCT00734760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: face-to-face education and counseling intervention
Study: NCT02218476

Intervention type: DRUG
Group type: OTHER
Intervention: CoQ10

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT01674595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVANZ olea
Description: Immunotherapy Olea europaea
Study: NCT03956797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recens Cooling Anesthesia Device
Description: Application of cooling anesthesia device prior to intravitreal injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recens Cooling Anesthesia Device
Description: Application of cooling anesthesia device prior to intravitreal injection